MarketPulse

pharmaceutical valuation

2 articles
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Eli Lilly's GLP-1 Dominance Masks Valuation Risks for Long-Term Investors

$LLY dominates GLP-1 market with strong Mounjaro, Zepbound sales but trades at 40x P/E—well above pharma peers—raising concerns about priced-in perfection.
PFELLYNVOGLP-1 drugsZepbound
Investing.comInvesting.com··Itai Smidt

Novo Nordisk Reassesses Growth Outlook Following CagriSema Trial Setback

Novo Nordisk stock drops 15.9% after CagriSema obesity drug fails trial versus competitor tirzepatide, signaling intensifying competition in the GLP-1 market despite Wegovy's strength.
LLYNVOGLP-1 drugsWegovy